Cardiac POC Testing Devices Market by Product, Device Type, Application, End-User

List of Tables

The Cardiac POC Testing Devices Market was valued at USD 1.36 billion in 2023 and is projected to grow to USD 1.52 billion in 2024, with a CAGR of 12.36%, reaching USD 3.08 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.36 billion
Estimated Year [2024]	USD 1.52 billion
Forecast Year [2030]	USD 3.08 billion
CAGR (%)	12.36%

The cardiac point-of-care (POC) testing market has evolved rapidly, driven by a confluence of technological advances, changing clinical needs, and demand for faster, reliable diagnostics. This dynamic field is redefining the way healthcare providers screen, diagnose, and manage cardiac conditions. Recent developments in biomarker detection and portable device engineering have resulted in highly efficient methods to rapidly assess cardiac health at the bedside or in remote settings.

Innovation and precision in diagnostic technology have become crucial for ensuring timely intervention in cardiac emergencies. As trends in patient care shift towards decentralization and patient-centric models, the relevance and applications of cardiac POC testing devices are expanding. The landscape for these devices is continuously set to experience transformative growth as the integration of advanced biomarker tests and sophisticated device engineering meets an urgent need for improved accuracy and operational flexibility.

This comprehensive overview explores the various angles of the cardiac POC testing market, shedding light on transformative market shifts, detailed segmentation insights, regional opportunities, major players, actionable strategic recommendations, and a persuasive call-to-action for decision-makers looking to capitalize on these developments.

Transformative Shifts Redefining Cardiac POC Testing

In recent years, the cardiac POC testing domain has undergone transformative shifts propelled by both technological breakthroughs and changes in clinical demand. A surge in innovation has led to the development of novel diagnostic methods that enhance early detection and ongoing monitoring of cardiac conditions. This transformation is marked by improvements in accuracy, speed, and the ability to deliver near-patient testing solutions, which ultimately contribute to better patient outcomes.

Key drivers of this shift include the integration of digital health tools and AI-assisted diagnostics, which are streamlining result interpretation and enabling more personalized treatment pathways. Advances in miniaturization and sensor technology have allowed instruments to become more portable and user-friendly, elevating their role across diverse healthcare settings. Furthermore, the focus on reducing the turnaround time for cardiac biomarker tests, alongside the integration of automated systems, is instrumental in mitigating diagnostic delays during critical periods.

These dynamic changes are shaping a market environment where rapid and accurate diagnosis is not just desirable but essential. As healthcare systems globally continue to strive for efficiency and improved patient care, the ongoing enhancements in device capabilities and diagnostic accuracy will undoubtedly set future standards and open up new avenues for market growth.

Key Insights from Market Segmentation Analysis

Understanding the intricate layers of market segmentation provides a robust framework for identifying opportunities and challenges within the cardiac POC testing market. An analysis based on product differentiates the market into segments such as Cardiac Biomarker Test, Consumables & Accessories, and Devices. The Cardiac Biomarker Test segment is itself subdivided further into specific tests including B-Type Natriuretic Peptide, Creatine Kinase-MB (CK-MB) Fraction, D-dimer Tests, Myoglobin Tests, and Troponin Tests. Meanwhile, the Devices segment is examined through the lens of Analyzers and Imaging & Monitoring Devices, highlighting the importance of both analytical performance and real-time monitoring capabilities.

Examining the market by device type exposes a division into Bench-top POC Devices, Handheld POC Devices, and Wearable POC Devices, each offering unique pros and cons based on clinical needs, portability, and ease-of-use. The application-based segmentation further divides the market into Diagnostics & Screening and Monitoring, reflecting the dual roles these devices serve in both early detection and ongoing management of cardiac conditions. Additionally, an analysis by end-user segments into Ambulatory Surgical Centers, Diagnostic Laboratories, Home Settings, and Hospitals, emphasizing the versatile utilization of these technologies across a spectrum of care environments.

This granular segmentation strategy illuminates key trends and requirements by blending technical specifications with practical applications. It helps stakeholders appreciate not only the technical diversity of the offerings but also the varied clinical settings that are adopting these diagnostic innovations. Such insights pave the way for targeted strategies that address the nuanced needs of each segment, ensuring that product development and market positioning are aligned with evolving clinical demands and patient-care paradigms.

Based on Product, market is studied across Cardiac Biomarker Test, Consumable & Accessories, and Devices. The Cardiac Biomarker Test is further studied across B-Type Natriuretic Peptide, Creatine Kinase-MB [CK-MB] Fraction, D-dimer Tests, Myoglobin Tests, and Troponin Tests. The Devices is further studied across Analyzers and Imaging & Monitoring Devices.

Based on Device Type, market is studied across Bench-top POC Devices, Handheld POC Devices, and Wearable POC Devices.

Based on Application, market is studied across Diagnostics & Screening and Monitoring.

Based on End-User, market is studied across Ambulatory Surgical Centers, Diagnostic Laboratories, Home Settings, and Hospitals.

Regional Insights Driving Market Expansion

The global market for cardiac POC testing is shaped significantly by regional dynamics that influence both technology adoption and regulatory frameworks. In the Americas, robust healthcare infrastructure coupled with a strong focus on innovation in diagnostics fuels the pace of adoption while meeting high clinical standards. The region is characterized by a mature market environment with significant investments in research and development aimed at refining cardiac biomarker tests and associated devices.

Across Europe, the Middle East, and Africa, there is a growing acknowledgment of the importance of decentralized testing solutions, underpinned by strategic government initiatives and supportive healthcare policies. Sophisticated healthcare networks and a rising emphasis on patient monitoring have contributed to the expansion of POC testing solutions in this region. In particular, improving accessibility and reducing diagnostic time barriers have been pivotal in driving market penetration.

The Asia-Pacific region presents a dynamic growth landscape, characterized by rapid urbanization, rising healthcare awareness, and significant efforts to upgrade medical infrastructure. Emerging economies in this area have witnessed accelerated investments in healthcare technology, while simultaneous policy reforms and technological adoptions are enhancing access to advanced diagnostics. The region remains a hub of technological innovation, where investments in both centralized and decentralized diagnostic tools are propelling market growth and transforming how patient care is delivered.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Shaping the Market

The cardiac POC testing arena is bolstered by contributions from several influential companies whose innovations and market strategies are redefining diagnostic excellence. Industry frontrunners such as Abbott Laboratories, ACON Laboratories, Inc., and Alfa Scientific Designs, Inc. have developed state-of-the-art diagnostic tools that combine sensitivity, specificity, and user-friendly interfaces. Other key players like Bio-Rad Laboratories, Inc., Cipla Limited, and Compagnie Merieux Alliance SAS are equally pivotal in expanding global reach and driving technology adoption.

Notable multinational corporations such as Danaher Corporation, F. Hoffmann-La Roche Ltd, and Medtronic plc continue to invest heavily in R&D to refine existing offerings and develop next-generation devices. Innovative enterprises like Getein Biotech, Inc., LifeSign LLC, and Nano-Ditech Corp. are making significant strides by introducing cutting-edge technologies that cater to emerging markets. Additional contributions from Nexus Dx, Inc., Nova Biomedical Corporation, and Polymer Technology Systems, Inc. by Sinocare, Precision Biosensor, Inc., QuidelOrtho Corporation, Sekisui Chemical Co., Ltd., Siemens Healthineers AG, and Werfen, S.A. further underscore the highly competitive and collaborative nature of this market.

Each of these companies brings a unique blend of technological excellence and strategic market positioning. Their continued drive towards innovation, combined with an increasing emphasis on reliability and performance, is set to propel the overall growth of cardiac POC testing solutions across various clinical applications and geographies. These industry leaders not only shape market trends but also establish benchmarks that other players aspire to, continually encouraging advancements in the field.

The report delves into recent significant developments in the Cardiac POC Testing Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories, Inc., Alfa Scientific Designs, Inc., Bio-Rad Laboratories, Inc., Cipla Limited, Compagnie Merieux Alliance SAS, Danaher Corporation, F. Hoffmann-La Roche Ltd, Getein Biotech, Inc., Laboratory Corporation of America Holdings, LifeSign LLC, Medtronic plc, Merck KGaA, Nano-Ditech Corp., Nexus Dx, Inc., Nova Biomedical Corporation, Polymer Technology Systems, Inc. by Sinocare, Precision Biosensor, Inc., QuidelOrtho Corporation, Sekisui Chemical Co., Ltd., Siemens Healthineers AG, and Werfen, S.A.. Strategic Recommendations for Market Leadership

For industry leaders aiming to capitalize on the expanding cardiac POC testing landscape, a strategic approach that integrates innovation, market intelligence, and customer-centric service is essential. Based on current industry developments, it is recommended that companies invest robustly in research and development to pioneer next-generation diagnostic tools that offer enhanced accuracy and speed. Forming strategic partnerships with research institutions and technology innovators can lead to breakthrough improvements in device performance, particularly in the realm of miniaturization and integrated digital platforms.

Market leaders should also focus on building resilient supply chains and optimizing manufacturing processes to ensure rapid scalability and cost-effectiveness. Tailoring product portfolios to meet the specific requirements of segmented market groups-ranging from comprehensive biomarker tests to versatile devices suitable for both clinical and home settings-will be vital. Furthermore, leveraging data analytics to understand consumer behavior and regional disease patterns can provide a competitive edge in customizing solutions that address local healthcare challenges.

Emphasis should be placed on expanding market presence in regions with high growth potential while remaining adaptive to regulatory changes and technological advancements. Building strong customer support networks and training programs can ensure that new technologies are effectively implemented and sustained. By adopting a holistic and agile approach, companies can safeguard their market share and drive ongoing success in a competitive and evolving field.

Conclusion: Paving the Way for a Healthier Future

In conclusion, the landscape of cardiac POC testing devices is marked by rapid innovation, diverse clinical applications, and substantial growth opportunities. Technological advancements are continuously reshaping the industry, enhancing the accuracy and speed of diagnostic tests while providing critical support in both emergent and routine care settings. Detailed segmentation insights reveal the multifaceted nature of this market, from specialized biomarker tests to advanced device categories that cater to various clinical and home environments.

The regional dynamics underscore the importance of targeted strategies, given the differing regulatory frameworks, technological maturity, and healthcare infrastructures across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Furthermore, the active role of key market players is instrumental in setting industry standards and driving adoption through continuous innovation and strategic market expansion.

Ultimately, these insights not only provide a roadmap for current market trends but also highlight the pivotal role that strategic planning and technological integration play in shaping the future of cardiac care. As stakeholders work together to advance the state of diagnostic health, the collective efforts contribute significantly to improving patient outcomes and fostering a healthier, more proactive approach to cardiac management.

Product Code: MRR-02026C4CB4BE

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of cardiac disorders and rising geriatric population globally
  - 5.1.1.2. Inclination toward the early detection and diagnosis of patients
  - 5.1.1.3. Favorable government support for cardiac health
- 5.1.2. Restraints
  - 5.1.2.1. Potential risk of product recall in Cardiac POC testing devices
- 5.1.3. Opportunities
  - 5.1.3.1. Implementation of unique & new troponin-based test
  - 5.1.3.2. Positive investment and startup ecosystem
- 5.1.4. Challenges
  - 5.1.4.1. Limitations and concerns associated with the accuracy of cardiac POC testing devices
5.2. Market Segmentation Analysis
- 5.2.1. Product: Favorable regulatory approvals for various cardiac POC testing devices
- 5.2.2. Device Type: Exploration of wearable POC devices to provide convenient homecare for managing heart conditions
- 5.2.3. Application: Critical role played by effective diagnostics & screening procedures in the management of cardiac diseases
- 5.2.4. End-User: Extensive and comprehensive care provided by hospitals for improving cardiac health
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Cardiac POC Testing Devices Market, by Product

6.1. Introduction
6.2. Cardiac Biomarker Test
- 6.2.1. B-Type Natriuretic Peptide
- 6.2.2. Creatine Kinase-MB [CK-MB] Fraction
- 6.2.3. D-dimer Tests
- 6.2.4. Myoglobin Tests
- 6.2.5. Troponin Tests
6.3. Consumable & Accessories
6.4. Devices
- 6.4.1. Analyzers
- 6.4.2. Imaging & Monitoring Devices

7. Cardiac POC Testing Devices Market, by Device Type

7.1. Introduction
7.2. Bench-top POC Devices
7.3. Handheld POC Devices
7.4. Wearable POC Devices

8. Cardiac POC Testing Devices Market, by Application

8.1. Introduction
8.2. Diagnostics & Screening
8.3. Monitoring

9. Cardiac POC Testing Devices Market, by End-User

9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Diagnostic Laboratories
9.4. Home Settings
9.5. Hospitals

10. Americas Cardiac POC Testing Devices Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cardiac POC Testing Devices Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cardiac POC Testing Devices Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Siemens Healthineers launches NT-proBNPII assay on Atellica platform to enhance heart failure diagnosis and speed patient care
- 13.3.2. F. Hoffmann-La Roche AG launches NT-proBNP point-of-care test on cobas h 232 to enhance early detection and management of CVD and heart failure in diabetes patients
- 13.3.3. Analytics for Life and CorVista Health receive FDA clearance for non-invasive CorVista System with Pulmonary Hypertension
- 13.3.4. Eko Health, Inc. and Mayo Clinic secure FDA clearance for AI-driven low ejection fraction detection
- 13.3.5. SpinChip Diagnostics receives NOK 115 million investment from bioMerieux to commercialize next-generation cardiac POC testing devices
- 13.3.6. Roche to acquire LumiraDx's microfluidic point-of-care technology to advance cardiovascular diagnostics
- 13.3.7. Primary Healthtech's Mobilab device offers early detection of heart and chronic diseases with IoT integration
- 13.3.8. EDX Medical Group Plc. acquires Hutano Diagnostics Ltd. to develop advanced smartphone-integrated POC tests
- 13.3.9. EDX Medical Group acquires Hutano Diagnostics to revolutionize rapid healthcare tests with advanced diagnostic technology enhancing speed, accuracy, and cost-effectiveness
- 13.3.10. Cipla launches cippoint, POC testing device to expand diagnostics portfolio with CE IVD approval, enhancing rapid clinical decision-making and market penetration
13.4. Strategy Analysis & Recommendation
- 13.4.1. F. Hoffmann-La Roche Ltd.
- 13.4.2. Siemens Healthineers AG
- 13.4.3. Abbott Laboratories
- 13.4.4. Danaher Corporation
- 13.4.5. Werfen, S.A.

Companies Mentioned

1. Abbott Laboratories
2. ACON Laboratories, Inc.
3. Alfa Scientific Designs, Inc.
4. Bio-Rad Laboratories, Inc.
5. Cipla Limited
6. Compagnie Merieux Alliance SAS
7. Danaher Corporation
8. F. Hoffmann-La Roche Ltd
9. Getein Biotech, Inc.
10. Laboratory Corporation of America Holdings
11. LifeSign LLC
12. Medtronic plc
13. Merck KGaA
14. Nano-Ditech Corp.
15. Nexus Dx, Inc.
16. Nova Biomedical Corporation
17. Polymer Technology Systems, Inc. by Sinocare
18. Precision Biosensor, Inc.
19. QuidelOrtho Corporation
20. Sekisui Chemical Co., Ltd.
21. Siemens Healthineers AG
22. Werfen, S.A.